Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label, Multiple Ascending Dose Study of the Safety, Tolerability, and Biological Activity of Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

NCT06701721 is registered in ClinicalTrials.gov with Therini Bio Pty Ltd as lead sponsor.

NCT NCT06701721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06701721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label, Multiple Ascending Dose Study of the Safety, Tolerability, and Biological Activity of Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
Lead sponsor
Therini Bio Pty Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
December 20, 2024
Completion date
May 31, 2027
Enrollment
21 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, diabetic retinopathy